• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Trends in Lipoprotein(a) Testing at the University of Pennsylvania Health Systems from 2012-2021
Lipoprotein(a) [Lp(a)] is an independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Elevated Lp(a) levels are associated with a higher risk for myocardial infarction, coronary artery disease, aortic stenosis, and stroke. Lp(a) levels are primarily genetically driven and minimally impacted by diet and lifestyle, so a single measurement can identify individuals with elevated levels. However, Lp(a) screening has not been widely integrated into clinical practice in the United States.
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Archna Bajaj, Lakshmi Parvathinathan, Marjorie Risman, Ahmad Alsattari, Daniel J. Rader Tags: Best Practices in Lipid Management Source Type: research

Economic Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Low Surgical Risk: Results from the PARTNER 3 Trial
CONCLUSIONS: For patients with severe aortic stenosis and low surgical risk similar to those enrolled in the PARTNER 3 trial, transfemoral TAVR with the SAPIEN 3 valve is cost saving compared with SAVR at 2 years and is projected to be economically attractive in the long run as long as there are no substantial differences in late death between the 2 strategies. Long-term follow-up will be critical to ultimately determine the preferred treatment strategy for low-risk patients from both a clinical and economic perspective.PMID:37154049 | DOI:10.1161/CIRCULATIONAHA.122.062481
Source: Circulation - May 8, 2023 Category: Cardiology Authors: Benjamin Z Galper Khaja M Chinnakondepalli Kaijun Wang Elizabeth A Magnuson Michael Lu Vinod H Thourani Susheel Kodali Raj Makkar Howard C Herrmann Samir Kapadia Mathew Williams John Webb Craig R Smith Michael J Mack Martin B Leon David J Cohen PARTNER In Source Type: research

The PARTNER 3 Trial at 2 Years: What We've Learned and What Time Will Tell
Based on data from large, industry-sponsored randomized prospective studies, the United States Food and Drug Administration (FDA) has approved both balloon-expandable and self-expanding transcatheter aortic valve replacement (TAVR) devices for use in aortic stenosis patients at low, intermediate and high-risk for surgical aortic valve replacement (SAVR).1-6 High-risk device approval was based on 1-year data, which was reasonable due to the actuarial life expectancies of the cohort.1, 2 Intermediate-risk approval for the balloon-expandable Sapien XT (Edwards Lifesciences, Irvine, California) system was largely based on data...
Source: Journal of Cardiothoracic and Vascular Anesthesia - May 28, 2021 Category: Anesthesiology Authors: Peter J. Neuburger, Kinjal M. Patel, Prakash A. Patel Source Type: research

A Composite Metric for Benchmarking Site Performance in TAVR: Results from the STS/ACC TVT Registry
Conclusions: There are substantial variations in the quality of TAVR care received in the United States, and 11% of sites were identified as providing care below the average level of performance. Further study is necessary to determine structural, process-related, and technical factors associated with high- and low-performing sites.PMID:33947202 | DOI:10.1161/CIRCULATIONAHA.120.051456
Source: Circulation - May 5, 2021 Category: Cardiology Authors: Nimesh D Desai Sean M O'Brien David J Cohen John Carroll Sreekanth Vemulapalli Suzanne V Arnold John K Forrest Vinod H Thourani Ajay J Kirtane Brian O'Neill Pratik Manandhar David M Shahian Vinay Badhwar Joseph E Bavaria Source Type: research

Oversized versus Non-oversized Prosthesis: Midterm Outcomes after Transcatheter Aortic Valve Replacement Using SAPIEN 3 Valve
Conclusion Oversizing reduces the risk of device failure and intraprocedural postdilation but increases the risk of PPI. Early and midterm morbidity and mortality after OS and nOS with S3 are comparable. [...] Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents  |  Abstract  |  Full text
Source: The Thoracic and Cardiovascular Surgeon - July 19, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Useini, Dritan Beluli, Blerta Christ, Hildegard M ügge, Andreas Patsalis, Polykarpos Schl ömicher, Markus Haldenwang, Peter Bechtel, Matthias Strauch, Justus Tags: Original Cardiovascular Source Type: research

Comparison of a Complete Percutaneous versus Surgical Approach to Aortic Valve Replacement and Revascularization in Patients at Intermediate Surgical Risk: Results from the Randomized SURTAVI Trial.
CONCLUSIONS: For patients at intermediate surgical risk with severe AS and non-complex CAD (SYNTAX score ≤ 22), a complete percutaneous approach of TAVR and PCI is a reasonable alternative to SAVR and CABG. CLINICAL TRIAL REGISTRATION: URL: www.clinicaltrials.gov Unique Identifier: NCT01586910. PMID: 31476897 [PubMed - as supplied by publisher]
Source: Circulation - September 2, 2019 Category: Cardiology Authors: Søndergaard L, Popma JJ, Reardon MJ, Van Mieghem NM, Deeb GM, Kodali S, George I, Williams MR, Yakubov SJ, Kappetein AP, Serruys PW, Grube E, Schiltgen MB, Chang Y, Engstrøm T, SURTAVI Trial Investigators Tags: Circulation Source Type: research

In ‐hospital outcomes of transcatheter versus surgical aortic valve replacement in non‐teaching hospitals
ConclusionsTAVR conferred similar in ‐hospital mortality and major peri‐procedural complications compared with SAVR in non‐teaching hospitals. For those with limited access to teaching hospitals, non‐teaching hospitals appear to be a reasonable option for candidates of aortic valve replacement for severe aortic stenosis.
Source: Catheterization and Cardiovascular Interventions - November 8, 2018 Category: Cardiovascular & Thoracic Surgery Authors: Tomo Ando, Oluwole Adegbala, Pedro A. Villablanca, Alexandros Briasoulis, Hisato Takagi, Cindy L. Grines, Theodore Schreiber, Tamim Nazif, Susheel Kodali, Luis Afonso Tags: VALVULAR AND STRUCTURAL HEART DISEASES Source Type: research

Early Outcomes With the Evolut PRO Repositionable Self-Expanding Transcatheter Aortic Valve With Pericardial Wrap
Conclusions The safety and efficacy results of this study support the use of the Evolut PRO System for the treatment of severe symptomatic aortic stenosis in patients who are at increased surgical risk, resulting in excellent hemodynamics and minimal paravalvular leak (The Medtronic TAVR 2.0 US Clinical Study; NCT02738853)
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 15, 2018 Category: Cardiology Authors: Forrest, J. K., Mangi, A. A., Popma, J. J., Khabbaz, K., Reardon, M. J., Kleiman, N. S., Yakubov, S. J., Watson, D., Kodali, S., George, I., Tadros, P., Zorn, G. L., Brown, J., Kipperman, R., Saul, S., Qiao, H., Oh, J. K., Williams, M. R. Tags: Structural: Focus on TAVR Source Type: research

Transcatheter Aortic Valve Replacement: OPTIMIZING OUTCOMES FOR HEALTHY RECOVERY
Transcatheter aortic valve replacement (TAVR) has been approved in the United States for intermediate and high-risk patients with severe symptomatic aortic stenosis. More than 80 000 TAVR procedures have been performed in the United States and the number is growing every year. Two valve designs are approved in the United States including the balloon expandable Edwards Sapien prosthesis and self-expanding CoreValve prosthesis. The PARTNER trial of the Sapien valve, involving patients who were considered inoperable, reported a 19% absolute risk reduction in mortality compared with medical therapy, with a number needed to tre...
Source: Journal of Cardiopulmonary Rehabilitation - January 1, 2018 Category: Rehabilitation Tags: Invited Review Source Type: research

1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement: Results From the First WIN-TAVI Registry
Conclusions Intermediate to high-risk women enrolled in this first ever all-women contemporary TAVR registry experienced a 1-year VARC-2 composite efficacy endpoint of 16.5%, with a low incidence of 1-year mortality and stroke. Prior revascularization and EuroSCORE I were independent predictors of the VARC-2 efficacy endpoint, whereas EuroSCORE I, baseline atrial fibrillation, and prior percutaneous coronary intervention were independent predictors of the 1-year death or stroke.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 1, 2018 Category: Cardiology Authors: Chieffo, A., Petronio, A. S., Mehilli, J., Chandrasekhar, J., Sartori, S., Lefevre, T., Presbitero, P., Capranzano, P., Tchetche, D., Iadanza, A., Sardella, G., Van Mieghem, N. M., Meliga, E., Dumonteil, N., Fraccaro, C., Trabattoni, D., Mikhail, G., Shar Tags: Focus on Cardiovascular Outcomes Among Women Source Type: research

Transcatheter Aortic Valve Replacement: OPTIMIZING OUTCOMES FOR HEALTHY RECOVERY
Transcatheter aortic valve replacement (TAVR) has been approved in the United States for intermediate and high-risk patients with severe symptomatic aortic stenosis. More than 80 000 TAVR procedures have been performed in the United States and the number is growing every year. Two valve designs are approved in the United States including the balloon expandable Edwards Sapien prosthesis and self-expanding CoreValve prosthesis. The PARTNER trial of the Sapien valve, involving patients who were considered inoperable, reported a 19% absolute risk reduction in mortality compared with medical therapy, with a number needed to tre...
Source: Journal of Cardiopulmonary Rehabilitation - December 28, 2017 Category: Rehabilitation Tags: Invited Review Source Type: research

Transcatheter Aortic Valve Replacement: OPTIMIZING OUTCOMES FOR HEALTHY RECOVERY.
Abstract Transcatheter aortic valve replacement (TAVR) has been approved in the United States for intermediate and high-risk patients with severe symptomatic aortic stenosis. More than 80 000 TAVR procedures have been performed in the United States and the number is growing every year. Two valve designs are approved in the United States including the balloon expandable Edwards Sapien prosthesis and self-expanding CoreValve prosthesis. The PARTNER trial of the Sapien valve, involving patients who were considered inoperable, reported a 19% absolute risk reduction in mortality compared with medical therapy, with a ...
Source: Journal of Cardiopulmonary Rehabilitation and Prevention - December 14, 2017 Category: Rehabilitation Authors: Goel K, Holmes DR Tags: J Cardiopulm Rehabil Prev Source Type: research